Antengene To Present Latest Results from TORCH-2 Study of ATG-008 in Advanced Solid Tumors in Poster Discussion at ASCO 2023

/PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to...

Related Keywords

Beijing ,China ,Australia ,Singapore ,South Korea ,Chicago ,Illinois ,United States ,Mccormick Place ,Shanghai ,Hong Kong ,Taiwan ,American ,Peter Qian ,Asia Pacific ,Hong Kong Stock Exchange ,Prnewswire Antengene Corporation Limited ,Company Annual ,Eastern Cooperative Oncology Group ,Antengene Corporation Limited ,American Society For Clinical Oncology Annual Meeting ,Antengene Corporation ,Mccormick Place Convention Center ,Corporation Limited ,Clinical Oncology Annual Meeting ,Poster Discussions ,Poster Discussion ,Family Zhang ,Chief Medical ,Developmental Therapeutics ,Discussion Session Date ,Central Time ,Beijing Time ,Cervical Cancer Cohort ,Nasopharyngeal Carcinoma ,Evaluation Did Not Identify ,Dose Limiting Toxicity ,Maximum Tolerated Dose ,Dose Escalation Phase ,Patients Beyond ,Mainland China ,Taiwan China ,Annual Report ,Hong Kong Stock ,